(-)-5-Methyl-8-hydroxy-(di-n-propylamino)tetralin: A new 5-HT(1A) receptor antagonist

European Journal of Medicinal Chemistry

Volumn 33, Issue 6, 1998, Pages 437-444

  Trillat, Anne Cécile ^a   Mathé Allainmat, Monique ^a   Brémont, Béatrice ^a   Malagié, Isabelle ^a   Jacquot, Christian ^a   Gardier, Alain M ^b   Langlois, Michel ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

5 HT(1A) receptor antagonist; Adenylyl cyclase activity; Serotonin; Tetralin

Indexed keywords

2 DIPROPYLAMINO 5 METHYL 8 TETRALINOL; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ADENYLATE CYCLASE; CYCLIC AMP; FORSKOLIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; ENZYME ACTIVITY; HIPPOCAMPUS; IN VITRO STUDY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RAT; SEROTONINERGIC SYSTEM;

EID: 0032100138     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(98)80044-5     Document Type: Article

References (32)

1. [1] Deakin J.F.W., J. Psychopharmacol. 7 ( 1993) 283-289.
2. [2] Zifa E., Fillion G., Pharmacol. Rev. 44 (1992) 401-458.
3. [3] Palacios J.M., Pazos A., Hoyer D., Characterization and mapping of 5-HT1A sites in the brain of animals and man. In: Dourish C.T., Ahlenius S., Hutson P.H. (Eds.), Brain 5-HT1A Receptors: Behavioural and Neurochcmical Pharmacology, VCH, Chichester, 1987, pp. 67-81.
4. [4] Adell A., Carceller A., Artigas F., J. Neurochem. 60 (1993) 1673-1681.
5. [5] Routledge C., Behav. Brain Res. 73 (1996) 153-156.
6. [6] (a) Dourish C.T., Hutson P.H., Curzon G., Trends Pharmacol. Sci. 7 (1986) 212-214;
7. 1A Receptors: Behavioural and Neurochemical Pharmacology, Ellis Horwood, Chichester, 1987, pp. 261-277.
8. [7] Yocca F.D., Hyslop D.K., Smith D.W., Maayani S., Eur. J. Pharmacol. 137 (1987) 293-294.
9. [8] Glennon R.A., Naiman N.A., Pierson ME., Titeler M., Lyon R.A., Weisberg E., Eur. J. Pharmacol. 154 (1988) 339-341.
10. [9] Schoeffter P., Fozard J.R., Stoll A., Siegl H., Seiler M.P., Hoyer D., Eur. J. Pharmacol. 244 (1993) 251-257.
11. [10] Cliffe I.A., Brightwell C.I., Fletcher A., Forster E.A., Mansell H.L., Reilly Y., Routledge C., White A.C., J. Med. Chem. 36 (1993) 1509-1510.
12. [11] Forster E.A., Cliffe I.A., Bill D.J., Dover G.M., Jones D., Reilly Y., Fletcher A., Eur. J. Pharmacol. 281 (1995) 81-88.
13. [12] Björk L., Cornfield J., Nelson D.L., Hillver S.-E., Andén N.-E., Lewander T., Hacksell U., J. Pharmacol. Exp. Ther. 258 (1991) 58-65.
14. [13] Fletcher A., Forster E.A., Bill D., Brown G., Cliffe I.A., Hartley I.E., Jones D.E., McLenachan A., Stanhope K.J., Critchley D.J.P., Childs K.J., Middlefell V.C., Lanfumey L., Corradetti R., Laporte A.-M., Gozlan H., Hamon M., Dourish C.T., Behav. Brain Res. 73 (1996) 337-353.
15. [14] Assié M.-B., Koek W., Eur. J. Pharmacol. 304 (1996) 15-21.
16. [15] Sylte I., Edvardsen O., Dahl S.G., Protein. Eng. 9 (1996) 149-160.
17. [16] (a) Langlois M., Brémont B., Rouselle D., Gaudy F., Eur. J. Pharmacol. 244 (1993) 77-87;
18. (b) Langlois M., Gaudy F., Shen S., Brémont B., BioMed. Chem. Lett. 3 (1993) 2035-2038.
19. [17] Langlois M., Gaudy F., Synth. Comm. 22 (1992) 1723-1734.
20. [18] Hall M.D., El Mestikawy S., Emerit M.B., Pichat L., Hamon M., Gozlan H., J. Neurochem. 44 (1985) 1685-1696.
21. [19] Hamon M.,Goetz C., Gozlan H., CNS Receptor Subtypes: Pharmacological Significance and Clinical Implications, Raven Press, New York, 1983.
22. [20] De Vivo M., Maayani S., J. Pharmacol. Exp. Ther, 238 (1986) 248-253.
23. [21] Salomon Y., Adv. Cyclic Nucl. Res. 10 (1979) 35-55.
24. [22] Hillver S-V., Björk L., Li L.-Y., Svensson B., Ross S., Andén N.-E., Hacksell U., J. Med. Chem. 33 (1990) 1541-1544.
25. [23] Trillat A.-C., Malagié I., Langlois M., Mathé-Allainmat M., Brémont B., Jacquot C., Gardier A.M., in: Society for NeuroScience, Annual Meeting, Washington D.C., 16-21 November 1996, 22, 527.7.
26. [24] Liu Y., Cortizo L., Yu H., Svensson B.E., Lewander T., Hacksell U., Eur. J. Med. Chem. 30 (1995) 277-286.
27. [25] Yang D., Soulier J.-L., Sicsic S., Mathé-Allainmat M., Brémont B., Croci T., Cardamone R., Aureggi G., Langlois M., J. Med. Chem. 40 (1997) 608-621.
28. [26] Cornfield L.J., Lambert G., Arvidsson L.-E., Mellin C., Vallgarda J., Hacksell U., Nelson D.L., Mol. Pharmacol. 39 (1991) 780-787.
29. [27] Murphy R.A., Kung H.F., Kung M.-P., Billing J., J. Med. Chem. 33 (1990) 171-178.
30. [28] Langlois M., Brémont B., Shen S., Poncet A., Andrieux J., Sicsic S., Serraz I., Mathé-Allainmat M., Renard P., Delagrange P., J. Med. Chem. 38 (1995) 2050-2060.
31. [29] Lowry O.H., Roseborough A.L., Farr A.L., Randall R.J., J. Biol. Chem. 193 (1951) 265-275.
32. [30] Hamon M., Fattaccini C.-M., Adrien J., Gallisot M.-C., Martin P., Gozlan H., J. Pharmacol. Exp. Ther. 246 (1988) 745-752.